The treatment of brain metastasis from breast cancer, role of blood-brain barrier disruption and early experience with trastuzumab

Rose Marie Tyson, D. Kraemer, Matthew A. Hunt, Leslie L. Muldoon, Peter Orbay, Leeza Maron, Kristoph Jahnke, Edward A. Neuwelt

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Therapeutic approaches in the treatment of metastatic systemic brain tumors from breast cancer have improved. As patients live longer, the potential for CNS sanctuary disease increases. Metastases to the brain are diagnosed in breast cancer patients at a rate of 10 to 20%. Median survival is only 3 to 12 months with current standard therapies of whole-brain radiotherapy, surgery and stereotactic radiosurgery, and can vary with the type of treatment given. Chemotherapy and immunotherapy using trastuzumab may be more effective against brain metastases if delivery to the tumor can be improved. Results: The treatment was well tolerated with acceptable bone marrow toxicity. Median overall survival was 45.4 weeks and the majority of patients achieved symptomatic relief with reduction of steroids. Methods & objectives: We evaluated the use of osmotic blood-brain barrier disruption chemotherapy, with or without monoclonal antibody, for the treatment of brain metastases from breast cancer. We are interested in the prospective evaluation of the combination of a monoclonal antibody, trastuzumab, with enhanced delivery of carboplatin and methotrexate chemotherapy. Discussion: The use of carboplatin and methotrexate with blood-brain barrier disruption showed efficacy in the treatment of metastatic breast cancer to the CNS. This is comparable to other modalities, and without cognitive loss. Quality of life is improved with the withdrawal of steroids. Conclusion: The long-term goal is to use combined chemotherapy and immunotherapy with radiosurgery to increase survival and avoid complications from other treatments.

Original languageEnglish
Pages (from-to)97-112
Number of pages16
JournalTherapy
Volume3
Issue number1
DOIs
Publication statusPublished - Jan 2006

Fingerprint

Blood-Brain Barrier
Breast Neoplasms
Neoplasm Metastasis
Brain
Drug Therapy
Radiosurgery
Carboplatin
Methotrexate
Immunotherapy
Therapeutics
Survival
Steroids
Monoclonal Antibodies
Central Nervous System Diseases
Trastuzumab
Brain Neoplasms
Radiotherapy
Bone Marrow
Quality of Life
Neoplasms

Keywords

  • Blood-brain barrier disruption
  • Carboplatin
  • Intraarterial
  • Metastasis
  • Methotrexate
  • Trastuzumab

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

The treatment of brain metastasis from breast cancer, role of blood-brain barrier disruption and early experience with trastuzumab. / Tyson, Rose Marie; Kraemer, D.; Hunt, Matthew A.; Muldoon, Leslie L.; Orbay, Peter; Maron, Leeza; Jahnke, Kristoph; Neuwelt, Edward A.

In: Therapy, Vol. 3, No. 1, 01.2006, p. 97-112.

Research output: Contribution to journalArticle

Tyson, Rose Marie ; Kraemer, D. ; Hunt, Matthew A. ; Muldoon, Leslie L. ; Orbay, Peter ; Maron, Leeza ; Jahnke, Kristoph ; Neuwelt, Edward A. / The treatment of brain metastasis from breast cancer, role of blood-brain barrier disruption and early experience with trastuzumab. In: Therapy. 2006 ; Vol. 3, No. 1. pp. 97-112.
@article{3c1a6979c5e243f39119ecedfc992f14,
title = "The treatment of brain metastasis from breast cancer, role of blood-brain barrier disruption and early experience with trastuzumab",
abstract = "Background: Therapeutic approaches in the treatment of metastatic systemic brain tumors from breast cancer have improved. As patients live longer, the potential for CNS sanctuary disease increases. Metastases to the brain are diagnosed in breast cancer patients at a rate of 10 to 20{\%}. Median survival is only 3 to 12 months with current standard therapies of whole-brain radiotherapy, surgery and stereotactic radiosurgery, and can vary with the type of treatment given. Chemotherapy and immunotherapy using trastuzumab may be more effective against brain metastases if delivery to the tumor can be improved. Results: The treatment was well tolerated with acceptable bone marrow toxicity. Median overall survival was 45.4 weeks and the majority of patients achieved symptomatic relief with reduction of steroids. Methods & objectives: We evaluated the use of osmotic blood-brain barrier disruption chemotherapy, with or without monoclonal antibody, for the treatment of brain metastases from breast cancer. We are interested in the prospective evaluation of the combination of a monoclonal antibody, trastuzumab, with enhanced delivery of carboplatin and methotrexate chemotherapy. Discussion: The use of carboplatin and methotrexate with blood-brain barrier disruption showed efficacy in the treatment of metastatic breast cancer to the CNS. This is comparable to other modalities, and without cognitive loss. Quality of life is improved with the withdrawal of steroids. Conclusion: The long-term goal is to use combined chemotherapy and immunotherapy with radiosurgery to increase survival and avoid complications from other treatments.",
keywords = "Blood-brain barrier disruption, Carboplatin, Intraarterial, Metastasis, Methotrexate, Trastuzumab",
author = "Tyson, {Rose Marie} and D. Kraemer and Hunt, {Matthew A.} and Muldoon, {Leslie L.} and Peter Orbay and Leeza Maron and Kristoph Jahnke and Neuwelt, {Edward A.}",
year = "2006",
month = "1",
doi = "10.1586/14750708.3.1.97",
language = "English",
volume = "3",
pages = "97--112",
journal = "Therapy",
issn = "2044-9038",
publisher = "Future Medicine Ltd.",
number = "1",

}

TY - JOUR

T1 - The treatment of brain metastasis from breast cancer, role of blood-brain barrier disruption and early experience with trastuzumab

AU - Tyson, Rose Marie

AU - Kraemer, D.

AU - Hunt, Matthew A.

AU - Muldoon, Leslie L.

AU - Orbay, Peter

AU - Maron, Leeza

AU - Jahnke, Kristoph

AU - Neuwelt, Edward A.

PY - 2006/1

Y1 - 2006/1

N2 - Background: Therapeutic approaches in the treatment of metastatic systemic brain tumors from breast cancer have improved. As patients live longer, the potential for CNS sanctuary disease increases. Metastases to the brain are diagnosed in breast cancer patients at a rate of 10 to 20%. Median survival is only 3 to 12 months with current standard therapies of whole-brain radiotherapy, surgery and stereotactic radiosurgery, and can vary with the type of treatment given. Chemotherapy and immunotherapy using trastuzumab may be more effective against brain metastases if delivery to the tumor can be improved. Results: The treatment was well tolerated with acceptable bone marrow toxicity. Median overall survival was 45.4 weeks and the majority of patients achieved symptomatic relief with reduction of steroids. Methods & objectives: We evaluated the use of osmotic blood-brain barrier disruption chemotherapy, with or without monoclonal antibody, for the treatment of brain metastases from breast cancer. We are interested in the prospective evaluation of the combination of a monoclonal antibody, trastuzumab, with enhanced delivery of carboplatin and methotrexate chemotherapy. Discussion: The use of carboplatin and methotrexate with blood-brain barrier disruption showed efficacy in the treatment of metastatic breast cancer to the CNS. This is comparable to other modalities, and without cognitive loss. Quality of life is improved with the withdrawal of steroids. Conclusion: The long-term goal is to use combined chemotherapy and immunotherapy with radiosurgery to increase survival and avoid complications from other treatments.

AB - Background: Therapeutic approaches in the treatment of metastatic systemic brain tumors from breast cancer have improved. As patients live longer, the potential for CNS sanctuary disease increases. Metastases to the brain are diagnosed in breast cancer patients at a rate of 10 to 20%. Median survival is only 3 to 12 months with current standard therapies of whole-brain radiotherapy, surgery and stereotactic radiosurgery, and can vary with the type of treatment given. Chemotherapy and immunotherapy using trastuzumab may be more effective against brain metastases if delivery to the tumor can be improved. Results: The treatment was well tolerated with acceptable bone marrow toxicity. Median overall survival was 45.4 weeks and the majority of patients achieved symptomatic relief with reduction of steroids. Methods & objectives: We evaluated the use of osmotic blood-brain barrier disruption chemotherapy, with or without monoclonal antibody, for the treatment of brain metastases from breast cancer. We are interested in the prospective evaluation of the combination of a monoclonal antibody, trastuzumab, with enhanced delivery of carboplatin and methotrexate chemotherapy. Discussion: The use of carboplatin and methotrexate with blood-brain barrier disruption showed efficacy in the treatment of metastatic breast cancer to the CNS. This is comparable to other modalities, and without cognitive loss. Quality of life is improved with the withdrawal of steroids. Conclusion: The long-term goal is to use combined chemotherapy and immunotherapy with radiosurgery to increase survival and avoid complications from other treatments.

KW - Blood-brain barrier disruption

KW - Carboplatin

KW - Intraarterial

KW - Metastasis

KW - Methotrexate

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=33646186266&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646186266&partnerID=8YFLogxK

U2 - 10.1586/14750708.3.1.97

DO - 10.1586/14750708.3.1.97

M3 - Article

AN - SCOPUS:33646186266

VL - 3

SP - 97

EP - 112

JO - Therapy

JF - Therapy

SN - 2044-9038

IS - 1

ER -